adjuvant therapy

• 

Adjuvant nivolumab plus ipilimumab for kidney cancer

By Sharon Deveson Kell|2022-08-01T12:14:50+00:001 Aug 2022|Drug treatments|

Adjuvant therapy is medication that is given after surgery to [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab for kidney cancer

• 

AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?

By Sharon Deveson Kell|2022-06-28T08:24:52+00:0028 Jun 2022|Drug treatments|

The 2022 American Urological Association (AUA) Annual Meeting included a [...]

Read More

Comments Off on AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?

• 

Can adjuvant everolimus prevent recurrence following surgery?

By Sharon Deveson Kell|2022-06-08T07:53:18+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can adjuvant everolimus prevent recurrence following surgery?

• 

Is early treatment with adjuvant therapy healthy, cost effective and wise: the patient perspective?

By Sharon Deveson Kell|2022-06-08T07:43:52+00:008 Jun 2022|Drug treatments|

Adjuvant therapy is medication that is given in addition to [...]

Read More

Comments Off on Is early treatment with adjuvant therapy healthy, cost effective and wise: the patient perspective?

• 

Treatment of people who relapse on adjuvant pembrolizumab

By Sharon Deveson Kell|2022-05-03T08:30:19+00:003 May 2022|Drug treatments|

Adjuvant treatment is treatment that is given after surgery to [...]

Read More

Comments Off on Treatment of people who relapse on adjuvant pembrolizumab

• 

ASCO GU 2022: Pembrolizumab as adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2022-02-24T08:21:37+00:0024 Feb 2022|Drug treatments|

Nephrectomy is the standard of care for advanced renal cell [...]

Read More

Comments Off on ASCO GU 2022: Pembrolizumab as adjuvant therapy for kidney cancer

• 

Adjuvant pembrolizumab gets positive opinion from the European CHMP

By Sharon Deveson Kell|2021-12-20T11:28:24+00:0020 Dec 2021|Drug treatments|

We have just learnt that the Committee for Medicinal Products [...]

Read More

Comments Off on Adjuvant pembrolizumab gets positive opinion from the European CHMP

• 

FDA approves adjuvant pembrolizumab for intermediate-high risk kidney cancer

By Sharon Deveson Kell|2021-11-18T15:33:54+00:0018 Nov 2021|Drug treatments|

The Food and Drug administration (FDA) in the USA has [...]

Read More

Comments Off on FDA approves adjuvant pembrolizumab for intermediate-high risk kidney cancer

• 

International Kidney Cancer Symposium (IKCS) 2021

By Sharon Deveson Kell|2021-11-08T09:57:32+00:008 Nov 2021|Cancer news|

The International Kidney Cancer Symposium (IKCS) 2021 took place in [...]

Read More

Comments Off on International Kidney Cancer Symposium (IKCS) 2021

• 

Risks and benefits of adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2021-11-03T14:45:23+00:003 Nov 2021|Drug treatments|

Treatment of people with intermediate to high risk renal cell [...]

Read More

Comments Off on Risks and benefits of adjuvant therapy for kidney cancer